RPI ID: 2019-034-401
Innovation Summary: This invention describes a method for producing cellulose-nanoclay hemostatic nanocomposite fibers. The process involves dissolving cellulose in a room-temperature ionic liquid and integrating nanoclay particles to form a homogenous solution. The resulting fibers exhibit dramatically reduced human plasma coagulation times, enhancing their potential for rapid blood clotting applications. The nanocomposite structure leverages the synergistic effects of cellulose and nanoclay to improve biocompatibility and hemostatic performance.
Challenges / Opportunities: Current hemostatic materials often suffer from slow clotting times or poor biocompatibility. This technology addresses the need for faster-acting, safer wound treatment solutions. Opportunities exist to integrate these fibers into medical textiles, wound dressings, or surgical tools. Further development could explore scalability and regulatory pathways for clinical use.
Key Benefits / Advantages: ✔ Rapid plasma coagulation ✔ Biocompatible material composition ✔ Scalable fiber production method ✔ Potential for integration into existing medical devices ✔ Enhanced mechanical properties from nanoclay reinforcement
Applications: • Emergency wound care and trauma treatment • Surgical hemostatic tools • Military field dressings • Biomedical textiles
Keywords: Hemostasis, Nanocomposite fibers, Cellulose, Nanoclay, Plasma coagulation, Biomedical materials
Intellectual Property: Published patent application: US20220111113A1 (17/427288)